The role of pathology in the predictive oncology of solid tumours
Authors:
Pavel Fabian
Authors place of work:
Masarykův onkologický ústav Brno, Oddělení onkologické a experimentální patologie
Published in the journal:
Čas. Lék. čes. 2010; 149: 462-463
Category:
Review Article
Summary
Recently, a new generation of pharmacons that are aimed to hit specific molecular targets has entered the oncology. Currently, testing of tumour tissue for the presence of particular molecules is needed. These molecular entities predict probability of response to the targeted therapy. On a model of steroid hormone receptors and HER2 status testing a process of the predictive diagnostics is demonstrated. A contemporary concept of predictive oncology in the Czech Republic consisting of six „Predictive Oncology Laboratories“ is described. Surgical pathology is shown as a key partner in the predictive oncology system.
Key words:
predictive oncology.
Zdroje
1. Early Breast Cancer Trialists’ Collaborative Group 1998. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–1467.
2. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty year results of the Naples GUN Randomised Trial: Predictive factors of adjuvant tamoxifen effi cacy in early breast cancer. Clin Cancer Res 2003; 9: 1039–1046.
3. Dowsett M, Houghton J, Iden C, et al. Benefi t from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006; 17(5): 818–826.
4. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–2648.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783–792.
6. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3): 719–726.
7. Viani GA, Afonso SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7: 153.
8. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fl uorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13(1): 228–233.
9. Robert NJ, Eiermann W, Pienkowski, et al. BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up. J Clin Oncol. Abstract 19647 in 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25(18S).
10. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007; 131(1): 118–145.
11. Sobin LH, Wittekind CH. (eds.) TNM Classification of Malignant Tumours, Sixth Edition. New York, USA: Wiley-Liss 2002.
12. http://www.linkos.cz/odbornici/onkologie/klin_registr.php?t=4
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Significance of TDM, phenotyping and genotyping for the correct drug dosage
- Hereditary thrombophilias – recommendations for genetic testing in the clinical praxis
- Pharmacogenetic aspects of current pharmacotherapy
- Pharmacogenetics in cardiovascular diseases therapy – treatment according guidelines or according the individual requirement?